Below are the most recent publications written about "Pyrimidines" by people in Profiles.
-
Kassaye I, Alyafaie A, Zhang K, Lifton J, Gordan JD, Kelley RK, Yung M. Cataracts Associated With Fibroblast Growth Factor Receptor Inhibitors for Cholangiocarcinoma. JAMA Ophthalmol. 2024 Dec 01; 142(12):1109-1113.
-
Finan JM, Di Niro R, Park SY, Jeong KJ, Hedberg MD, Smith A, McCarthy GA, Haber AO, Muschler J, Sears RC, Mills GB, Gmeiner WH, Brody JR. The polymeric fluoropyrimidine CF10 overcomes limitations of 5-FU in pancreatic ductal adenocarcinoma cells through increased replication stress. Cancer Biol Ther. 2024 Dec 31; 25(1):2421584.
-
Imam IA, Al Adawi S, Liu X, Ellingson S, Brainson CF, Moseley HNB, Zinner R, Zhang S, Shao Q. L858R/L718Q and L858R/L792H Mutations of EGFR Inducing Resistance Against Osimertinib by Forming Additional Hydrogen Bonds. Proteins. 2025 Mar; 93(3):673-683.
-
Talasila S, Lee E, Teichner EM, Siegfried EC, Jackson Cullison SR. Analysis of publicly available adverse events reported for pediatric patients treated with Janus kinase inhibitors. Pediatr Dermatol. 2024 Nov-Dec; 41(6):1040-1046.
-
Burgei J, Alsheimer KM, Lantry J, Hehn B. Mediastinal lymphadenopathy due to VEXAS syndrome. BMJ Case Rep. 2024 Aug 08; 17(8).
-
Matesanz SE, Brigatti KW, Young M, Yum SW, Strauss KA. Preemptive dual therapy for children at risk for infantile-onset spinal muscular atrophy. Ann Clin Transl Neurol. 2024 Jul; 11(7):1868-1878.
-
Flammer LJ, Ellis H, Rivers N, Caronia L, Ghidewon MY, Christensen CM, Jiang P, Breslin PAS, Tordoff MG. Topical application of a P2X2/P2X3 purine receptor inhibitor suppresses the bitter taste of medicines and other taste qualities. Br J Pharmacol. 2024 Sep; 181(17):3282-3299.
-
Chen MF, Song Z, Yu HA, Sequist LV, Lovly CM, Mitchell EP, Moscow JA, Gray RJ, Wang V, McShane LM, Rubinstein LV, Patton DR, Williams PM, Hamilton SR, Umemura Y, Tricoli JV, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT. Phase II Study of Osimertinib in Patients With Epidermal Growth Factor Receptor Mutations: Results From the NCI-MATCH ECOG-ACRIN (EAY131) Trial Subprotocol E. JCO Precis Oncol. 2024 Apr; 8:e2300454.
-
Gladwin MT, Gordeuk VR, Desai PC, Minniti C, Novelli EM, Morris CR, Ataga KI, De Castro L, Curtis SA, El Rassi F, Ford HJ, Harrington T, Klings ES, Lanzkron S, Liles D, Little J, Nero A, Smith W, Taylor JG, Baptiste A, Hagar W, Kanter J, Kinzie A, Martin T, Rafique A, Telen MJ, Lalama CM, Kato GJ, Abebe KZ. Riociguat in patients with sickle cell disease and hypertension or proteinuria (STERIO-SCD): a randomised, double-blind, placebo controlled, phase 1-2 trial. Lancet Haematol. 2024 May; 11(5):e345-e357.
-
Appleman LJ, Kim SE, Harris WB, Pal SK, Pins MR, Kolesar J, Agarwal N, Parikh RA, Vaena DA, Ryan CW, Hashmi M, Costello BA, Cella D, Dutcher JP, DiPaola RS, Haas NB, Wagner LI, Carducci MA. Randomized, Double-Blind Phase III Study of Pazopanib Versus Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease After Metastasectomy: ECOG-ACRIN E2810. J Clin Oncol. 2024 Jun 10; 42(17):2061-2070.